- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02914834
Acupuncture for Individuals With Stable Angina (AIMS-A)
October 4, 2021 updated by: Judith Schlaeger, University of Illinois at Chicago
Feasibility Testing of a Randomized Controlled Trial of Acupuncture to Improve Symptoms for Individuals With Stable Angina (AIMS-A)
This RCT aims to determine if it is possible to perform acupuncture on men and women diagnosed with stable angina who have symptoms, chest pain, and/or chest discomfort.
The investigators want to determine if acupuncture reduces the pain and other symptoms of angina, chest pain, and chest discomfort.
The investigators also want to examine whether this study is acceptable to the participants, and by carrying out this study the investigators will be able to tell how many participants they will need in a future larger study to further test acupuncture to reduce the symptoms of angina in women.
Study Overview
Status
Terminated
Intervention / Treatment
Detailed Description
The investigators are conducting a RCT aimed at gathering feasibility, and initial efficacy for a randomized controlled trial (RCT) to test the effect of acupuncture on anginal symptoms, chest pain, and chest discomfort in men and women.
The investigators long term goal is pain and symptom management resulting in improved functional status and quality of life for men and women with stable angina, chest pain, and chest discomfort.
This study will include 69 community dwelling men and women with a medically confirmed diagnosis of stable angina, chest pain which includes non-ischemic or ischemic cardiomyopathy, microvascular coronary dysfunction (MCD), heart failure with preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF), or chest discomfort whose pain and associated symptoms have not been completely controlled with guideline-directed medical management.
The investigators will use a randomized attention control design with 13 men and women assigned to initial acupuncture and 13 to control.
Participants in the experimental group will receive a standardized acupuncture point prescription two treatments per week, for 5 weeks.
The attention control group will receive non-pain related video health education over 5 weeks equal to the approximate 10 hours of treatment for the acupuncture group.
Study Type
Interventional
Enrollment (Actual)
27
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- University of Illinois at Chicago College of Nursing
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion criteria:
- provision of a verified diagnosis from a care provider
- male or female sex
- at least 21 years of age
- intermittent angina symptoms (pain, pressure, or discomfort in the chest or other areas of the upper body)
- medical confirmation of a diagnosis of stable angina for at least 6 months
medical confirmation of a diagnosis of chest pain including non-ischemic or ischemic cardiomyopathy
medical confirmation of a diagnosis of microvascular coronary dysfunction (MCD)
medical confirmation of a diagnosis of heart failure with preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF) medical confirmation of chest discomfort.
Exclusion criteria:
- pregnancy
- chronic obstructive pulmonary disease (COPD) causing pain or associated symptoms
- autoimmune dysfunction
- use of steroid medications
- concomitant physical therapy
- biofeedback
- massage
- additional acupuncture
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Device Acupuncture
Standardized acupuncture protocol twice per week for 5 weeks for a total of 10 sessions
|
Standardized acupuncture treatment administered for 30 minutes each session
|
Active Comparator: Non-pain related video health education
The attention control group will receive non-pain related video health education over 5 weeks equal to the approximate 10 hours of treatment for the acupuncture group.
|
Attention control group will watch health education videos the equivalent of 10 hours from randomization up to study completion.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility of Study Protocol
Time Frame: After 10th acupuncture treatment, at 5 weeks post-baseline (study completion)
|
Feasibility was measured by recruitment (%), retention (%), completion (%).
Feasibility was defined as ≥ 80% recruitment, ≥75% retention following enrollment, and ≥ 80% completion.
|
After 10th acupuncture treatment, at 5 weeks post-baseline (study completion)
|
Protocol Acceptability Scale for Treating Angina With Acupuncture
Time Frame: After 10th acupuncture treatment, at 5 weeks post-baseline (study completion)
|
Protocol Acceptability Scale for Treating Angina with Acupuncture is a 9-item instrument used to measure acceptability of the study processes and protocols.
Items are measured on a 0 to 2 scale, where 0 means "did not like the study and did not like acupuncture", and 2 means "liked the study and liked acupuncture".
The protocol was deemed to have high acceptability if 80% of participants scored ≥ 80% of possible points on the acceptability scale.
The investigators calculated the mean score for each of the 9 questions in each arm, divided the total score for the 9 questions by the maximum possible points for the measure (18 x number of participants in each arm), and converted the total mean scores to percentage of participants who liked the study/liked acupuncture in each arm.
|
After 10th acupuncture treatment, at 5 weeks post-baseline (study completion)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Average Pain Intensity From the McGill Pain Questionnaire
Time Frame: From before first treatment at baseline to after 10th acupuncture treatment (study completion) at 5 weeks
|
Average Pain Intensity from the McGill Pain Questionnaire is the average of pain now, least pain in the past 24 hours, and worst pain in the past 24 hours.
Average Pain Intensity is scored on a 0 to 10 Likert type scale with 0 = no pain and 10 = excruciating pain.
Pain intensity is the pre-specified outcome measure, while pain now and least and worst pain are values used to calculate average pain intensity and were not specified outcome measures.
|
From before first treatment at baseline to after 10th acupuncture treatment (study completion) at 5 weeks
|
Seattle Angina Questionnaire-7 (SAQ-7)
Time Frame: From before first treatment at baseline to after 10th acupuncture treatment (study completion) at 5 weeks
|
The instrument consists of 7 items measuring functional status, symptoms, and quality of life on participants.
Item responses are coded sequentially from worst to best status and range from 1 to 6, except Quality of Life (range 1-5).
Scores are generated for each domain and are scaled 0 to 100, with 0 denoting the worst and 100 the best possible status.
|
From before first treatment at baseline to after 10th acupuncture treatment (study completion) at 5 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Inflammatory Biomarkers Blood Test
Time Frame: From before first treatment at baseline to after 10th acupuncture treatment (study completion) at 5 weeks
|
Inflammatory biomarkers between the acupuncture and control group [interleukin (IL)- 2, IL-4, IL-6, IL-8, IL-10, IL-18; tumor necrosis factor alpha (TNF-α)].
Changes in these values from before first treatment at baseline to after 10th acupuncture treatment at 5 weeks is reported.
|
From before first treatment at baseline to after 10th acupuncture treatment (study completion) at 5 weeks
|
Inflammatory Biomarkers Blood Test- Mean Change C-reactive Protein (CRP)
Time Frame: From before first treatment at baseline to after 10th acupuncture treatment (study completion) at 5 weeks.
|
Inflammatory biomarker CRP between the acupuncture and control group.
Changes in these values from before first treatment at baseline to after 10th acupuncture treatment at 5 weeks is reported.
|
From before first treatment at baseline to after 10th acupuncture treatment (study completion) at 5 weeks.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Holli A DeVon, PhD, University of Illinois at Chicago
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 15, 2019
Primary Completion (Actual)
March 16, 2020
Study Completion (Actual)
March 16, 2020
Study Registration Dates
First Submitted
August 13, 2016
First Submitted That Met QC Criteria
September 23, 2016
First Posted (Estimate)
September 26, 2016
Study Record Updates
Last Update Posted (Actual)
October 7, 2021
Last Update Submitted That Met QC Criteria
October 4, 2021
Last Verified
October 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2016-0642
- R21NR017705-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
US Department of Veterans AffairsCompleted
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
Clinical Trials on Acupuncture
-
University of ZurichCharite University, Berlin, Germany; First Teaching Hospital of Tianjin University...CompletedExperimental Dental PainSwitzerland
-
Federal University of São PauloCompleted
-
University of SkövdeCompleted
-
National Research Centre of Complementary and Alternative...Norwegian Acupuncture CollegeUnknown
-
Chengdu University of Traditional Chinese MedicineChongqing Medical University; Hunan University of Traditional Chinese MedicineCompletedFunctional Dyspepsia | Postprandial Distress SyndromeChina
-
University of MichiganMassachusetts General Hospital; National Center for Complementary and Integrative...Completed
-
Chang Gung Memorial HospitalRecruitingIntracranial HemorrhagesTaiwan
-
University Medicine GreifswaldRecruitingGagging During Transesophageal EchocardiographyGermany
-
Huazhong University of Science and TechnologyThe University of Hong Kong; Heilongjiang University of Chinese Medicine; Hubei...CompletedPolycystic Ovary SyndromeChina
-
China Medical University HospitalNot yet recruiting